Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Preferred Shares Issued Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt repayments

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization EBIAT Leases Long-Term Debt Repayments Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Preferred Shares Issued Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Receivables - Other Shares Issued Shares Outstanding Shares Outstanding Short-Term Debt repayments

Corbus Pharmaceuticals Holdings (CRBP) Short-Term Debt repayments (2020 - 2024)

Corbus Pharmaceuticals Holdings has reported Short-Term Debt repayments over the past 4 years, most recently at $73000.0 for Q4 2023.

For Q4 2023, Short-Term Debt repayments fell 26.21% year-over-year to $73000.0; the TTM value through Dec 2023 reached $426000.0, down 50.86%, while the annual FY2024 figure was $301000.0, 29.34% down from the prior year.
Short-Term Debt repayments for Q4 2023 was $73000.0 at Corbus Pharmaceuticals Holdings, up from $51000.0 in the prior quarter.
Over five years, Short-Term Debt repayments peaked at $330108.0 in Q2 2022 and troughed at $51000.0 in Q3 2023.
A 4-year average of $198208.5 and a median of $175575.5 in 2020 define the central range for Short-Term Debt repayments.
Biggest five-year swings in Short-Term Debt repayments: increased 8.64% in 2021 and later plummeted 54.29% in 2022.
Year by year, Short-Term Debt repayments stood at $199217.0 in 2020, then increased by 8.64% to $216437.0 in 2021, then plummeted by 54.29% to $98928.0 in 2022, then dropped by 26.21% to $73000.0 in 2023.
Business Quant data shows Short-Term Debt repayments for CRBP at $73000.0 in Q4 2023, $51000.0 in Q3 2023, and $151934.0 in Q2 2023.